E-Mail
NEW YORK, NY (March 1, 2021) By harnessing the immune system against cancer, immunotherapies have revolutionized the way some types of cancer are treated. But most patients across cancer types do not respond, and in most cases, scientists are at a loss as to why.
Researchers at Columbia and MIT have created a new technique that can uncover nearly all of the tricks cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments.
The researchers tested their new technique with cancer cells and matching immune cells from melanoma patients and identified previously unknown resistance mechanisms to immune checkpoint inhibitors, a powerful and widely used class of immunotherapy drugs.
Posted on 346
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the publication of a study in the journal
Nature Medicine that
used NanoString’s GeoMx® Digital Spatial Profiler (DSP) and the new Whole Transcriptome Atlas (WTA) to profile sarcoma tissue. The research was led by a team from the Broad Institute in Cambridge, Massachusetts. The paper, entitled “Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma,” can be found here.(https://www.nature.com/articles/s41591-020-01212-6)
Nature Medicine publishes first peer-reviewed study using GeoMx DSP with next generation sequencing readout. (Photo: Business Wire)
Press release content from Business Wire. The AP news staff was not involved in its creation.
Nature Medicine Publishes First Study Utilizing NanoString’s GeoMx Digital Spatial Profiler Whole Transcriptome Atlas
February 9, 2021 GMT
Nature Medicine publishes first peer-reviewed study using GeoMx DSP with next generation sequencing readout. (Photo: Business Wire)
Nature Medicine publishes first peer-reviewed study using GeoMx DSP with next generation sequencing readout. (Photo: Business Wire)
SEATTLE (BUSINESS WIRE) Feb 9, 2021
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the publication of a study in the journal
Nature Medicine that